Matches in Wikidata for { <http://www.wikidata.org/entity/Q61443351> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- Q61443351 description "article" @default.
- Q61443351 description "im Januar 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q61443351 description "wetenschappelijk artikel" @default.
- Q61443351 description "наукова стаття, опублікована в січні 2019" @default.
- Q61443351 name "Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective" @default.
- Q61443351 name "Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective" @default.
- Q61443351 type Item @default.
- Q61443351 label "Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective" @default.
- Q61443351 label "Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective" @default.
- Q61443351 prefLabel "Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective" @default.
- Q61443351 prefLabel "Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective" @default.
- Q61443351 P1433 Q61443351-F64EAFFE-7D4F-4512-BA0D-B99B32ECFFFA @default.
- Q61443351 P1476 Q61443351-F2AFB3FD-39C5-4C16-997E-757773CCC65B @default.
- Q61443351 P2093 Q61443351-303507B8-6220-4FF1-A2C6-E324D107E2DB @default.
- Q61443351 P2093 Q61443351-3C84DEF2-A890-44C4-9EDA-11A05DFDBD34 @default.
- Q61443351 P2093 Q61443351-541D127B-6E3F-4809-B73A-73153A68595F @default.
- Q61443351 P2093 Q61443351-9E5EC555-CA07-4373-AEA8-D953929CE2A8 @default.
- Q61443351 P2093 Q61443351-A08AB568-C3AC-4F05-B67A-1C8684000DC3 @default.
- Q61443351 P2093 Q61443351-B3C7D37F-1603-4917-B91E-06BECDB02922 @default.
- Q61443351 P2093 Q61443351-B9A53418-24A5-4D83-B1B5-731D322ED6A5 @default.
- Q61443351 P2093 Q61443351-CBAAD3E1-A8B3-4D7E-A95B-029830284C9A @default.
- Q61443351 P2093 Q61443351-F5DB8959-4363-43BD-9249-36733619237E @default.
- Q61443351 P275 Q61443351-bf5ebbdf-4f7c-4ea1-aef3-08e8646bafc3 @default.
- Q61443351 P2860 Q61443351-8AA8FD21-4F02-4F11-AC24-2BBA0EFAD5E3 @default.
- Q61443351 P2888 Q61443351-1725E49B-85ED-48F0-9510-0687EC251EC2 @default.
- Q61443351 P304 Q61443351-AA854F29-FE93-4B4D-A7A4-EF54E4E7ECAF @default.
- Q61443351 P31 Q61443351-05891719-A3B7-4DB2-8357-629DB389574E @default.
- Q61443351 P31 Q61443351-B0234AE6-3307-4F49-A7A8-D3AE904E77B7 @default.
- Q61443351 P356 Q61443351-BD3FF2E3-6601-4237-845F-2BAF585FEFC8 @default.
- Q61443351 P407 Q61443351-217F9236-09F7-4750-AC69-1EF053C17634 @default.
- Q61443351 P433 Q61443351-FF05EC74-1B59-4482-917B-F7B2B316E901 @default.
- Q61443351 P478 Q61443351-72814869-C8AF-4814-B06F-213565A41A90 @default.
- Q61443351 P50 Q61443351-9DF17F38-6C61-48CD-83A1-44F43C79D090 @default.
- Q61443351 P577 Q61443351-FEE590D3-99BD-46AF-9859-594740C92226 @default.
- Q61443351 P6179 Q61443351-0D9662D6-CBB9-462F-9AB9-580502CE0E9A @default.
- Q61443351 P6216 Q61443351-b4a01cbc-ee4e-4d49-a363-90085dd93908 @default.
- Q61443351 P698 Q61443351-1CD813B0-AF30-4D28-99C2-963984B5BA6B @default.
- Q61443351 P921 Q61443351-1338CE85-6E6A-4D6E-B53C-4F6236F2FFFE @default.
- Q61443351 P932 Q61443351-3FD19ABA-23D8-496D-9553-B53AE436ECE4 @default.
- Q61443351 P356 S12931-019-0985-2 @default.
- Q61443351 P698 30691468 @default.
- Q61443351 P1433 Q7315904 @default.
- Q61443351 P1476 "Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective" @default.
- Q61443351 P2093 "B Seewoodharry Buguth" @default.
- Q61443351 P2093 "F García-Río" @default.
- Q61443351 P2093 "I P Naya" @default.
- Q61443351 P2093 "J Whalen" @default.
- Q61443351 P2093 "L A Vallejo-Aparicio" @default.
- Q61443351 P2093 "M Miravitlles" @default.
- Q61443351 P2093 "M T Driessen" @default.
- Q61443351 P2093 "N A Risebrough" @default.
- Q61443351 P2093 "Y Asukai" @default.
- Q61443351 P275 Q20007257 @default.
- Q61443351 P2860 Q59330107 @default.
- Q61443351 P2888 s12931-019-0985-2 @default.
- Q61443351 P304 "18" @default.
- Q61443351 P31 Q13442814 @default.
- Q61443351 P31 Q1348305 @default.
- Q61443351 P356 "10.1186/S12931-019-0985-2" @default.
- Q61443351 P407 Q1860 @default.
- Q61443351 P433 "1" @default.
- Q61443351 P478 "20" @default.
- Q61443351 P50 Q58316702 @default.
- Q61443351 P577 "2019-01-28T00:00:00Z" @default.
- Q61443351 P6179 "1111750933" @default.
- Q61443351 P6216 Q50423863 @default.
- Q61443351 P698 "30691468" @default.
- Q61443351 P921 Q199804 @default.
- Q61443351 P932 "6348614" @default.